Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| MEK inhibitor | MEK inhibitor is a potent MEK inhibitor with antitumor potency. Uses: Scientific research. Group: Signaling pathways. CAS No. 334951-92-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-12202. |  |
| MEK Inhibitor | Selective dual MEK5 kinase inhibitor, with IC50 values of 4.3, 810, 1800, and >6300 nM for MEK5, ERK5, TGFbR1 and other closely related kinases respectively. Synonyms: MEK inhibitor; BIX 02188; BIX02188; BIX-02188; 1H-Indole-6-carboxamide, 3-[[[3-[ (dimethylamino) methyl]phenyl]amino]phenylmethylene]-2, 3-dihydro-N-methyl-2-oxo-, (3Z)-. Grades: >98%. CAS No. 334951-92-7. Molecular formula: C26H26N4O2. Mole weight: 426.51. |  |
| InSolution MEK1/2 Inhibitor III, PD0325901 - CAS 391210-10-9 | The MEK1/2 Inhibitor III, PD0325901, also referenced under CAS 391210-10-9, controls the biological activity of MEK1/2. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. Group: Fluorescence/luminescence spectroscopy. |  |
| MEK1 Derived Peptide Inhibitor 1 | It is a peptide composed of the first 13 amino acids of the human mitogen-activated protein kinase kinase-1 (MEK1). It inhibits the in vitro activation of ERK2 by MEK1. Synonyms: H-Met-Pro-Lys-Lys-Lys-Pro-Thr-Pro-Ile-Gln-Leu-Asn-Pro-OH; L-methionyl-L-prolyl-L-lysyl-L-lysyl-L-lysyl-L-prolyl-L-threonyl-L-prolyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-asparagyl-L-proline. Grades: >98%. Molecular formula: C68H118N18O17S. Mole weight: 1491.84. | |
| PD-325901, Free Base (PD 0325901, MEK1/2 Inhibitor III) | A selective and ATP non-competitive MEK inhibitor that suppresses the phosphorylation of ERK in murine colon 26 tumors (IC50 = 0.33nM). In combination with the GSK-3 inhibitor CHIR99021, prevents cell differentiation and sustains self-renewal of embryonic stem (ES) cells. PD 325901 is an inhibitor of mitogen activated protein kinase kinase (MEK or MAPKK). The potency, solubility and effectiveness of PD 325901 are greatly improved compared to PD 184352 (CI-1040). Group: Biochemicals. Alternative Names: N-[(2R)-2,3-Dihydroxypropoxy]-3,4-difluoro-2[(2-fluoro-4-iodophenyl)amino]-benzamide; PD 0325901, MEK1/2 Inhibitor III. Grades: Highly Purified. CAS No. 391210-10-9. Pack Sizes: 10mg, 25mg. US Biological Life Sciences. |  Worldwide |
| 10Z-Hymenialdisine | 10Z-Hymenialdisine is a pan kinase inhibitor (IC50 values are 6, 10, 22, 28, 35, 40, 70, 80, 100, 470, 500, 600, 700 and 700 nM for MEK1, GSK-3β, Cdk1/cyclin B, Cdk5/p25, CK1, Cdk2/cyclin A, Cdk2/cyclin E, ASK-γ, Cdk3/cyclin E, Erk1, PKCγ, Cdk4/cyclin D1, Cdk6/cyclin D2 and PKCα, respectively). 10Z-Hymenialdisine inhibits NF-κB activation and suppresses inflammatory gene expression. Synonyms: Hymenialdisine; (Z)-Hymenialdisine; 4-(2-amino-4-oxo-1H-imidazol-5(4H)-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8(1H)-one. Grades: ≥97% by HPLC. CAS No. 82005-12-7. Molecular formula: C11H10BrN5O2. Mole weight: 324.13. | |
| 10Z-Hymenialdisine | Insecticidal and cytotoxic. Potent NF-kappaB inhibitor. Inhibits various pro-inflammatory cytokines such as IL-1, IL-2, IL-6, IL-8, TNF-alpha and nitric oxide (NO) in a variety of cell lines. ATP-competitive kinase inhibitor. Inhibits DNA damage checkpoint at G2, cyclin-dependent kinases CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, CDK5/p25, GSK-3beta and casein kinase 1 (CK1). Potent mitogen-activated protein kinase kinase-1 (MEK-1) inhibitor. MARK (microtubule affinity-regulating kinase) inhibitor. Group: Biochemicals. Grades: Highly Purified. CAS No. 82005-12-7. Pack Sizes: 500ug, 1mg. Molecular Formula: C??H??BrN?O?, Method for Determining. US Biological Life Sciences. | Worldwide |
| 10Z-Hymenialdisine (Hymenialdisine, 4-(2-Amino-4-oxo-2-imidazolidin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one) | Isolated from sponge Axinella carteri. A potent inhibitor of mitogen-activated protein kinase kinase-1 (MEK-1) (IC50=6nm). Blocks the in vivo phosphorylation of the microtubule-binding protein tau at sites that are hyperphosphorylated by glycogen synthase kinase-b (GSK-3b) and CDK5/p35 in Alzheimers disease. Inhibitor of DNA damage checkpoint at G2 phase (IC50=6uM), cyclin-dependent kinases CDK1/cyclin B (IC50=22nm), CDK2/cyclin A (IC50=70 nm), CDK2/cyclin E (IC50=40nm), CDK4/cyclin D1 (IC50 = 600nm), CDK5/p25 (IC50=28nm), GSK-3b (IC50=10nm), and casein kinase 1 (CK1) (IC50=35nm). Group: Biochemicals. Grades: Highly Purified. CAS No. 82005-12-7. Pack Sizes: 250ug, 1mg. US Biological Life Sciences. | Worldwide |
| 1,2-Dimyristoyl-sn-glycero-3-phosphate Sodium Salt | 1,2-Dimyristoyl-sn-glycero-3-phosphate Sodium Salt is used to evaluate phosphatidic acids (PAs) in micelles, liposomes, and artificial membrane. Also, it is derived from (S)-(+)-2,2-Dimethyl-1,3-dioxolane-4-methanol (D472635), which is an MEK inhibitor with anti-tumor activity. Group: Biochemicals. Grades: Highly Purified. CAS No. 80724-31-8. Pack Sizes: 1mg. Molecular Formula: C31H60NaO8P. US Biological Life Sciences. | Worldwide |
| 1-Allylcyclopropane-1-sulfonyl Chloride | A MEK inhibitors; useful in the treatment of cancer and other hyperproliferative diseases. Group: Biochemicals. Alternative Names: 1- (2-Propen-1-yl) cyclopropanesulfonyl Chloride. Grades: Highly Purified. CAS No. 923032-59-1. Pack Sizes: 50mg. US Biological Life Sciences. | Worldwide |
| 2-(2-Boc-aminoethoxy)ethanol | 2-(2-Boc-aminoethoxy)ethanol is a reactant that has been used in the synthesis of RGD-conjugated MEK1/2 kinase inhibitors for integrin-targeted cancer therapy. Group: Biochemicals. Grades: Highly Purified. CAS No. 139115-91-6. Pack Sizes: 1g, 5g. Molecular Formula: C9H19NO4. US Biological Life Sciences. | Worldwide |
| 2-(2-Fluoro-4-iodoanilino)-3,4-difluorobenzoic Acid | Intermediate in the preparation of MEK inhibitors. Group: Biochemicals. Alternative Names: 3, 4-Difluoro-2-[ (2-fluoro-4-iodophenyl) amino]benzoic Acid; 3, 4-Difluoro-2- (2-fluoro-4-iodophenylamino) benzoic Acid. Grades: Highly Purified. CAS No. 391211-97-5. Pack Sizes: 500mg. US Biological Life Sciences. | Worldwide |
| 2-Fluoro-4-iodoaniline | 2-Fluoro-4-iodoaniline is widely used in the pharmaceutical, chemical and food industries as a fundamental building block to create a variety of important compounds. 2-Fluoro-4-iodoaniline is mostly known as a moiety of TAK-733, a selective inhibitor of mitogen-activated or extracellular signal-regulated protein kinase kinase 2 (MEK2). Group: Biochemicals. Grades: Highly Purified. CAS No. 29632-74-4. Pack Sizes: 25g, 50g. Molecular Formula: C6H5FIN, Molecular Weight: 237.01. US Biological Life Sciences. | Worldwide |
| 2-Methoxy-1-pyrroline | 2-Methoxy-1-pyrroline acts as a reagent in the design and preparation of dihydroindolones and dihydroindolizinones as orally available MEK inhibitors with potent in vivo antitumor efficacy. Synthesis and anti-HSV activity of methylenedioxy mappicine ketone analogs against herpes viruses. Group: Biochemicals. Grades: Highly Purified. CAS No. 5264-35-7. Pack Sizes: 500mg, 1g. Molecular Formula: C5H9NO, Molecular Weight: 99.13. US Biological Life Sciences. | Worldwide |
| 6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one | KP372-1 is a specific Akt inhibitor that demonstrates at least 10-fold selectivity against a panel of additional kinase targets, including CDK1, ERK1, GSK3β, LCK, MEK1, PKA, PKC, and S6K. It blocks Akt signalling through the PI3K pathway, and inhibits cell proliferation while inducing apoptosis of thyroid cancer cells. Synonyms: 6H-Indeno[1,2-e]tetrazolo[1,5-b][1,2,4]triazin-6-one. Grades: ≥95%. CAS No. 1374996-60-7. Molecular formula: C20H8N12O2. Mole weight: 448.4. | |
| AS-703026 | AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM). AS703026 induces pleiotropic anti-myeloma activity in vitro and in vivo. MEK inhibitors are useful in the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. Group: Biochemicals. Alternative Names: N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide. Grades: Highly Purified. CAS No. 1236699-92-5. Pack Sizes: 25mg. US Biological Life Sciences. | Worldwide |
| ASTX-029 | ASTX029 is a highly potent and selective dual-mechanism ERK inhibitor. ASTX029 inhibits both ERK catalytic activity and the phosphorylation of ERK itself by MEK, despite not directly inhibiting MEK activity. ASTX029 preferentially inhibited the proliferation of MAPK-activated cell lines, including those with BRAF or RAS mutations. ASTX029 also demonstrated activity in both in vitro and in vivo models of acquired resistance to MAPK pathway inhibitors. Uses: Designed for use in research and industrial production. Additional or Alternative Names: ASTX-029; ASTX029; ASTX 029. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 2095719-92-7. Molecular formula: C29H31ClFN5O5. Mole weight: 584.05. Purity: >98%. IUPACName: (R)-2-(6-(5-chloro-2-((tetrahydro-2H-pyran-4-yl)amino)pyrimidin-4-yl)-1-oxoisoindolin-2-yl)-N-((S)-1-(3-fluoro-5-methoxyphenyl)-2-hydroxyethyl)propanamide. Canonical SMILES: ClC(C(C1=CC=C2C(C(N([C@H](C)C(N[C@H](CO)C3=CC(OC)=CC(F)=C3)=O)C2)=O)=C1)=N4)=CN=C4NC5CCOCC5. Product ID: ACM2095719927. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Aurora Kinase Inhibitor VI, ZM447439 (4-(4-(N-Benzoylamino)anilino)-6- methoxy-7- (3- (1-morpholino) propoxy) quinazoline) | A cell-permeable quinazoline compound that targets the ATP binding pocket and an adjacent cleft and acts as a potent and reversible inhibitor of Aurora A and Aurora B (IC50=110 and 130nM, respectively) with moderate to excellent selectivity among closely related 16-kinase panel (IC50=0.88, 1.03 and 1.79uM for Lck, Src and MEK1, respectively, and IC50>10uM for Cdk1/2/4, Plk1, Chk1). Blocks phosphorylation of Histone H3-Ser10 in Xenopus cycling egg extracts at 20uM, and reduces mitotic spindle assembly. Shown to repress kinetochore localization of BubR1, Cenp-E, and Mad2, and arrest the growth of proliferating tumor cells. Group: Biochemicals. Grades: Highly Purified. CAS No. 331771-20-1. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| Avutometinib | Avutometinib (Ro 5126766) is a first-in-class dual MEK / RAF inhibitor that allosterically inhibits BRAF V600E , CRAF , MEK , and BRAF (IC 50 : 8.2, 56, 160 nM, and 190 nM, respectively). Uses: Scientific research. Group: Signaling pathways. Alternative Names: Ro 5126766; CH5126766. CAS No. 946128-88-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18652. | |
| AZD-8330 | AZD8330 is an orally active, selective MEK inhibitor with potential antineoplastic activity. AZD8330 specifically inhibits mitogen-activated protein kinase kinase 1 (MEK or MAP/ERK kinase1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. Synonyms: AZD8330; AZD-8330; AZD 8330; ARRY424704; ARRY 424704; ARRY-424704; ARRY704; ARRY-704; ARRY 704. Grades: 0.98. CAS No. 869357-68-6. Molecular formula: C16H17FIN3O4. Mole weight: 461.232. | |
| Bavachalcone | Bavachalcone inhibited osteoclast formation from precursor cells with the IC(50) of approximately 1.5 microg ml(-1). The activation of MEK, ERK, and Akt by receptor activator of nuclear factor kappaB ligand (RANKL), the osteoclast differentiation factor, was prominently reduced in the presence of bavachalcone. The induction of c-Fos and NFATc1, key transcription factors for osteoclastogenesis, by RANKL was also suppressed by bavachalcone. Bavachalcone exhibited a significant inhibitory effect on baculovirus-expressed BACE-1 in vitro. Bavachalcone had stronger inhibition on UGT1A1 and UGT1A7 than corylin which did not inhibit UGT1A1, UGT1A3, UGT1A7, UGT1A8, UGT1A10, and UGT2B4. Data fitting using Dixon and Lineweaver-Burk plots demonstrated the noncompetitive inhibition of bavachalcone against UGT1A1 and UGT1A7-mediated 4-MU glucuronidation reaction. The values of inhibition kinetic parameters (Ki) were 5.41 μ M and 4.51μ M for UGT1A1 and UGT1A7, respectively. Synonyms: Broussochalcone B. Grades: >98%. CAS No. 28448-85-3. Molecular formula: C20H20O4. Mole weight: 324.37. | |
| BAY-6035 | BAY-6035 is an inhibitor of SET and MYND domain-containing protein 3 (SMYD3) with IC50 of 70 nMm, which exhibits >100-fold selectivity for SMYD3 over other histone methyltransferases. BAY-6035 inhibits methylation of MEKK2 peptide in a cell-free assay and in cell. Synonyms: (2S)-1-(3-azabicyclo[3.1.0]hex-3-ylcarbonyl)-N-(2-cyclopropylethyl)-2,3,4,5-tetrahydro-2-methyl-4-oxo-1H-1,5-benzodiazepine-7-carboxamide. Grades: ≥95%. CAS No. 2247890-13-5. Molecular formula: C22H28N4O3. Mole weight: 396.48. | |
| BAY-6035 | BAY-6035 is a potent, selective and substrate-competitive inhibitor of SMYD3. BAY-6035 inhibits methylation of MEKK2 peptide with an IC 50 of 88 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2247890-13-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112080. | |
| BI-3406 | BI-3406 is Potent & Selective SOS1:KRAS Inhibitor (IC50=5 nM), which Opens a New Approach for Treating KRAS-Driven Tumours. BI 3406 selectively binds to SOS1 and blocks the interaction with KRAS, irrespective of the KRAS mutation. BI 3406 causes RAS GTP and pERK reduction and inhibits cell growth of KRAS mutated cell lines, carrying most of the typical KRAS mutations (i.e. G12D, G12V, G13D and others). BI 3406, when administered orally to tumour bearing mice, causes a dose dependent tumour static effect that can be converted into regressions when combined with MEK1 inhibition. Uses: Designed for use in research and industrial production. Additional or Alternative Names: BI-3406; BI 3406; BI3406. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 2230836-55-0. Molecular formula: C23H25F3N4O3. Mole weight: 462.47. Purity: >98%. IUPACName: N-((R)-1-(3-amino-5-(trifluoromethyl)phenyl)ethyl)-7-methoxy-2-methyl-6-(((S)-tetrahydrofuran-3-yl)oxy)quinazolin-4-amine. Canonical SMILES: C[C@H](C1=CC(N)=CC(C(F)(F)F)=C1)NC2=C3C(C=C(OC)C(O[C@H]4CCOC4)=C3)=NC(C)=N2. Product ID: ACM2230836550. Alfa Chemistry ISO 9001:2015 Certified. | |
| BI-847325 | BI-847325 is an orally available dual inhibitor of mitogen-activated protein kinase kinase (MEK) and Aurora kinases, with potential antineoplastic activity. Upon oral administration, MEK/Aurora kinase inhibitor BI 847325 selectively binds to and inhibits the activity of MEK, which both prevents the activation of MEK-dependent effector proteins and inhibits growth factor-mediated cell signaling. BI 847325 also binds to and inhibits the activity of the Aurora kinases A, B and C which may disrupt the assembly of the mitotic spindle apparatus, prevent chromosome segregation, and inhibit both cellular division and proliferation in Aurora kinase-overexpressing tumor cells. Uses: Designed for use in research and industrial production. Additional or Alternative Names: BI-847325; BI 847325; BI847325. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 1207293-36-4. Molecular formula: C29H28N4O2. Mole weight: 464.57. Purity: >98%. IUPACName: (Z)-3-(3-((4-((dimethylamino)methyl)phenylamino)(phenyl)methylene)-2-oxoindolin-6-yl)-N-ethylpropiolamide. Canonical SMILES: O=C(NCC)C#CC1=CC(NC/2=O)=C(C=C1)C2=C(NC3=CC=C(CN(C)C)C=C3)/C4=CC=CC=C4. Product ID: ACM1207293364-1. Alfa Chemistry ISO 9001:2015 Certified. | |
| BI-847325 | BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Synonyms: BI-847325; BI 847325; BI847325. Grades: 98%. CAS No. 1207293-36-4. Molecular formula: C29H28N4O2. Mole weight: 464.56. | |
| Binimetinib | Binimetinib is an oral, highly selective MEK inhibitor. Synonyms: MEK162; MEK-162; MEK 162; ARRY162; ARRY-162; ARRY 162; ARRY438162, Binimetinib; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide. Grades: >98%. CAS No. 606143-89-9. Molecular formula: C17H15BrF2N4O3. Mole weight: 441.233. | |
| Binimetinib | Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor. Binimetinib (MEK162) inhibits MEK with an IC 50 of 12 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MEK162; ARRY-162; ARRY-438162. CAS No. 606143-89-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-15202. | |
| BIX-02188 | BIX02188 is a potent MEK5-selective inhibitor with an IC50 of 4.3 nM. BIX02188 inhibits ERK5 catalytic activity, with an IC50 of 810 nM. Synonyms: BIX02188; BIX-02188; BIX 02188. CAS No. 334949-59-6. Molecular formula: C25H24N4O2. Mole weight: 412.493. | |
| BIX 02189 | BIX02189 is a selective inhibitor of MEK5 with IC50 of 1.5 nM, also inhibits ERK5 catalytic activity with IC50 of 59 nM, and does not inhibit closely related kinases MEK1, MEK2, ERK2, and JNK2. Synonyms: BIX02189; BIX-02189; (Z)-3- ( (3- ( (dimethylamino)methyl)phenylamino) (phenyl)methylene)-N, N-dimethyl-2-oxoindoline-6-carboxamide. Grades: >98%. CAS No. 1094614-85-3. Molecular formula: C27H28N4O2. Mole weight: 440.54. | |
| BMS 599626 dihydrochloride | BMS 599626 dihydrochloride is a potent and selective EGFR and ErbB2 inhibitor (IC50 = 22 nM and 32 nM, respectively), and also inhibits HER4 (IC50 = 190 nM). BMS 599626 displays 100-fold selectivity for EGFR and ErbB2 over VEGFR2, c-Kit, Lck, MET etc MEK and Lck. It can be used as an antiproliferative agent in vitro and anti-tumorigenic agent in vivo. Synonyms: BMS599626 dihydrochloride; BMS-599626 dihydrochloride; AC480 dihydrochloride; AC 480 dihydrochloride; AC-480 dihydrochloride; (3S)-3-Morpholinylmethyl-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-carbamate dihydrochloride; Carbamic acid, N-[4-[[1-[(3-fluorophenyl)methyl]-1H-indazol-5-yl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]-, (3S)-3-morpholinylmethyl ester, hydrochloride (1:2); (3S)-3-Morpholinylmethyl (4-{[1-(3-fluorobenzyl)-1H-indazol-5-yl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate dihydrochloride. Grades: ≥98% by HPLC. CAS No. 1781932-33-9. Molecular formula: C27H27FN8O3.2HCl. Mole weight: 603.48. | |
| BMS-599626 Hydrochloride | BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC 50 s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC 50=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: AC480 Hydrochloride. CAS No. 873837-23-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12010. | |
| B-Raf inhibitor 1 dihydrochloride | B-Raf inhibitor 1 is an inhibitor of B-Raf kinase with IC50 values of 0.31μM and 0.72μM for cell proliferation, respectively in A375 and HCT116. B-Raf is important in signal transduction and some mutant B-Raf occurs in cancer cells. The most common mutation of these is V600E, which makes B-Raf kinase constitutively active. B-Raf inhibitor 1 belongs to the type IIA inhibitors and binds to the DFG-out ATP-binding site of B-Raf. The selectivity of B-Raf inhibitor 1 is less than of other type inhibitors. Besides mutant B-Raf, it can also inhibit wild type B-Raf and other tyrosine kinase. In cells with wild type B-Raf, B-Raf inhibitor 1 can activate the RAF-MEK-ERK signaling pathway via Raf dimerization. The preclinical toxicity test shows B-Raf inhibitor 1 can induce hyperplasia in a mouse model. Synonyms: 1,5-Isoquinolinediamine, N1-(4-chlorophenyl)-6-methyl-N5-[3-(9H-purin-6-yl)-2-pyridinyl]-, hydrochloride (1:2). Grades: >98%. CAS No. 1191385-19-9. Molecular formula: C26H21Cl3N8. Mole weight: 551.86. | |
| CCT196969 | This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEK -ERK. CCT196969 also prevented growth of xenografts derived from patient tumours with resistance to BRAF and MEK inhibitors. Uses: Effective in drug-resistant braf mutant melanoma. Synonyms: CCT196969; CCT-196969; CCT 196969. N-[4-[(3,4-Dihydro-3-oxopyrido[2,3-b]pyrazin-8-yl)oxy]-2-fluorophenyl]-N'-[3-(1,1-dimethylethyl)-1-phenyl-1H-pyrazol-5-yl]urea. Grades: 98%. CAS No. 1163719-56-9. Molecular formula: C27H24FN7O3. Mole weight: 513.52. | |
| CCT241161 | This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells, inhibiting MEK -ERK. CCT 241161 also prevented growth of xenografts derived from patient tumours with resistance to BRAF and MEK inhibitors. Uses: Effective in drug-resistant braf mutant melanoma. Synonyms: CCT241161; CCT-241161; CCT 241161. 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-(methylthio)-4-((3-oxo-3,4-dihydropyrido[2,3-b]pyrazin-8-yl)oxy)phenyl)urea. Grades: 98%. CAS No. 1163719-91-2. Molecular formula: C28H27N7O3S. Mole weight: 541.62. | |
| CEP-32496 | CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respectively; insignificant affinity for MEK-1, MEK-2, ERK-1 and ERK-2. Phase 1/2. Synonyms: 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea; RXDX-105; RXDX 105; RXDX105; CEP32496; CEP-32496; CEP 32496; AC013773; AC 013773; AC-013773 Agerafenib. Grades: >98%. CAS No. 1188910-76-0. Molecular formula: C24H22F3N5O5. Mole weight: 517.46. | |
| CEP-32496 hydrochloride | CEP-32496, also known as AC013773, is an orally available v-raf murine sarcoma viral oncogene homolog B1 (B-raf) serine/threonine protein kinase inhibitor with potential antineoplastic activity. CEP-32496 specifically and selectively inhibits the activity of the mutated form (V600E) of B-raf kinase. This inhibits the activation of the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway and may result in a decrease in the proliferation of tumor cells expressing the mutated B-raf gene. The Raf mutation BRAF V600E, in which valine is substituted for glutamic acid at residue 600, is frequently found in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Synonyms: CEP-32496; CEP32496; CEP 32496; AC013773; AC 013773; AC-013773. CAS No. 1227678-26-3. Molecular formula: C24H23ClF3N5O5. Mole weight: 553.92. | |
| CHIR-99021 | A potent and highly selective inhibitor of glycogen synthase kinase-3beta (GSK-3b) (IC50 = 6.7nM). CHIR99021 has been shown to allow for long-term expansion of murine embryonic stem cells in a chemically-defined medium in conjunction with MEK/MAPK inhibitor PD184352 and fibroblast growth factor receptor (FGFR) inhibitor SU5402. Group: Biochemicals. Alternative Names: 6-((2-((4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2- yl) pyrimidin-2-yl) amino) ethyl) amino) nicotinonitrile; CT99021; CHIR 911. Grades: Highly Purified. CAS No. 252917-06-9. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| CI-1040 | CI-1040 is a MEK inhibitor, which demonstrated in vivo activity in preclinical animal models and subsequently became the first MEK inhibitor to enter clinical trial. CI-1040 suffered however from poor exposure due to its poor solubility and rapid clearance, and as a result, development of the compound was terminated. Synonyms: CI1040; CI-1040; CI 1040; PD184352; PD 184352; PD-184352. CAS No. 212631-79-3. Molecular formula: C17H14ClF2IN2O2. Mole weight: 478.662. | |
| CI-1040 | CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC 50 of 17 nM for MEK1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: PD 184352. CAS No. 212631-79-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-50295. | |
| CInQ-03 | CInQ-03 is a novel and specific MEK inhibitor both in vitro and in vivo. Synonyms: CInQ 03; CInQ03. CAS No. 500272-80-0. Molecular formula: C22H12ClN5O. Mole weight: 397.82. | |
| Cobimetinib | Cobimetinib (GDC-0973, RG7420) is a potent, orally available and highly selective MEK1 inhibitor with IC50 of 4.2 nM. It shows more than 100-fold selectively for MEK1 over MEK2 when tested against a panel of more than 100 serine-threonine and tyrosine kinases and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Synonyms: XL518; GDC-0973; RG7420. Grades: ≥98%. CAS No. 934660-93-2. Molecular formula: C21H21F3IN3O2. Mole weight: 531.31. | |
| Cobimetinib | Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral MEK1 inhibitor with an IC 50 of 4.2 nM for MEK1. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GDC-0973; XL518. CAS No. 934660-93-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13064. | |
| Cobimetinib hemifumarate | Cobimetinib, also known as GDC-0973 and XL-518, is a novel selective MEK inhibitor, and the IC50value against MEK1 is 4.2 nM, with potential antineoplastic activity. Synonyms: Methanone, [3,?4-difluoro-2-[(2-fluoro-4-iodophenyl)?amino]?phenyl]?[3-hydroxy-3-(2S)?-2-piperidinyl-1-azetidinyl]?-, (2E)?-2-butenedioate (2:1). CAS No. 1369665-02-0. Molecular formula: C21H21F3IN3O2.1/2C4H4O4. Mole weight: 589.35. | |
| Cobimetinib hemifumarate | Cobimetinib hemifumarate is a novel selective MEK1 inhibitor, and the IC 50 value against MEK1 is 4.2 nM. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GDC-0973 hemifumarate; XL-518 hemifumarate. CAS No. 1369665-02-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13064A. | |
| Cobimetinib racemate | Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GDC-0973 racemate; XL518 racemate. CAS No. 934662-91-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg. Product ID: HY-13078. | |
| Cobimetinib racemate | Cobimetinib racemate is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors. Synonyms: GDC-0973 racemate; XL-518; GDC 0973 racemate; XL 518; GDC0973 racemate; XL518. Grades: >98%. CAS No. 934662-91-6. Molecular formula: C21H21F3IN3O2. Mole weight: 531.31. | |
| Cobimetinib (R-enantiomer) | Cobimetinib (R-enantiomer) is a selective inhibitor of MEK. It is also known as mitogen activated protein kinase kinase (MAPKK) and is a key component of the RAS/RAF/MEK/ERK pathway, which is frequently activated in human tumors. Synonyms: GDC-0973 R-enantiomer; XL-518 R-enantiomer; GDC0973 R-enantiomer; XL518 R-enantiomer; GDC 0973 R-enantiomer; XL 518 R-enantiomer. Grades: >98%. CAS No. 934660-94-3. Molecular formula: C21H21F3IN3O2. Mole weight: 531.31. | |
| CRT 0066101 | Potent inhibitor of protein kinase D (PKD); inhibits all PKD isoforms (IC50 values are 1, 2 and 2.5nM for PKD1, PKD3 and PKD2 respectively). Exhibits selectivity for PKD against a panel of >90 protein kinases, including PKC-alpha, MEK, ERK, c-Raf and c- Src. Reduces proliferation and cell viability of pancreatic cancer cells expressing moderate levels of endogenous PKD1/2. Orally bioavailable. Group: Biochemicals. Alternative Names: 2-[4-[[(2R)-2-aminobutyl]amino]-2-pyrimidinyl]-4-(1-methyl-1H-pyrazol-4-yl)phenol dihydrochloride. Grades: Purified. CAS No. 1883545-60-5. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| CRT0066101 hydrochloride | CRT0066101 is an inhibitor of all three PKD isoforms (IC50s = 1, 2.5, and 2 nM for PKD1, PKD2, and PKD3, respectively). It exhibits selectivity for PKD against a panel of >90 protein kinases, including PKCα, PKBα, MEK, ERK, c-Raf, c-Src, and c-Abl. Synonyms: Phenol, 2-[4-[[(2R)-2-aminobutyl]amino]-2-pyrimidinyl]-4-(1-methyl-1H-pyrazol-4-yl)-, hydrochloride (1:3); (R)-2-(4-((2-Aminobutyl)amino)pyrimidin-2-yl)-4-(1-methyl-1H-pyrazol-4-yl)phenol trihydrochloride; 2-(4-{[(2R)-2-Aminobutyl]amino}pyrimidin-2-yl)-4-(1-methyl-1H-pyrazol-4-yl)phenol trihydrochloride. Grades: ≥95%. CAS No. 1781742-22-0. Molecular formula: C18H22N6O.3HCl. Mole weight: 447.79. | |
| Debromohymenialdisine | Protein kinase C (PKC) inhibitor. Inhibits the ATP binding site. Cytotoxic and insecticidal. G2 DNA damage checkpoint inhibitor. Check point kinases 1 (Chk1) and 2 (Chk2) inhibitor. Does not inhibit ataxia-telangiectasia mutated (ATM) or ATM-Rad3-related proteins. MAP kinase kinase 1 (MEK-1) inhibitor. Interleukin-1 (IL-1) inhibitor. Anti-osteoarthritic. Potential anti-Alzheimer agent. Group: Biochemicals. Grades: Highly Purified. CAS No. 75593-17-8, 125118-55-0. Pack Sizes: 100ug. Molecular Formula: C11H11N5O2. US Biological Life Sciences. | Worldwide |
| DL-1,2-Isopropylideneglycerol | A MEK inhibitor with antitumor activity. Synonyms: (2,2-dimethyl-1,3-dioxolan-4-yl)methanol. Grades: 98%. CAS No. 100-79-8. Molecular formula: C6H12O3. Mole weight: 132.16. | |
| E6201 | E6201 is a synthetic, fungal metabolite analogue inhibitor of mitogen-activated protein kinase kinase 1 (MEK-1) and mitogen-activated protein kinase kinase kinase 1 (MEKK-1) with potential antipsoriatic and antineoplastic activities. MEK-1/MEKK-1 inhibitor E6201 specifically binds to and inhibits the activities of MEK-1 and MEKK-1, which may result in the inhibition of tumor cell proliferation. MEK-1 and MEKK-1 are key components in the RAS/RAF/MEK/MAPK signaling pathway, which regulates cell proliferation and is frequently activated in human cancers. Synonyms: E6201; E 6201; E-6201; ER 806201; ER806201; ER-806201; LL-Z1640-2. CAS No. 603987-35-5. Molecular formula: C21H27NO6. Mole weight: 389.45. | |
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Synonyms: LGX818; LGX-818; LGX 818; Methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate. Grades: ≥98%. CAS No. 1269440-17-6. Molecular formula: C22H27ClFN7O4S. Mole weight: 540.011. | |
| Focal Adhesion Kinase Inhibitor III (FAK Inhibitor III, N-(4-tert-Butylbenzyl)-1,5-dimethyl-1,5-dihydropyrazolo[4,3-c][2,1]benzothiazin-8-amine-4,4-dioxide) | A cell-permeable pyrazolobenzothiazined ioxide compound that targets and locks FAK in its inactive conformation, resulting in preincubation time-dependent inhibition in kinase assays and FAK autophosphorylation in human prostate cancer PC3M-luc cells (IC50 = 7.1uM with 30 min inhibitor preincubation), while exhibiting little activity toward Akt1, Aurora B, HER2, MEK1, p38alpha, Pyk2, or Src even at concentrations as high as 10uM. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. Molecular Formula: C??H??N?O?S. US Biological Life Sciences. | Worldwide |
| G-573 | G-573 is an allosteric inhibitor of MEK that is both potent and selective. The IC(50) value for pERK inhibition in HCT116 tumours by G-573 was estimated to be 0.406? μM. The IC(50) values for tumour growth inhibition in HCT116 and H2122 were estimated to be 3.43 and 2.56?μM, respectively. ED(50) estimates in HCT116 and H2122 mouse xenograft models were estimated to be ~4.6 and 1.9?mg/kg/day, respectively. Synonyms: G 573; G573; 2-(3-chlorophenyl)benzimidazole; OTAVA-BB; 1H-Benzimidazole, 2-(3-chlorophenyl)-; Benzimidazole, 2-(m-chlorophenyl)-; 2-(3-Chlorophenyl)-1H-1,3-benzodiazole; 2-(3'-Chlorophenyl)benzimidazole; 2-(m-Chlorophenyl)benzimidazole. Grades: ≥95%. CAS No. 22868-35-5. Molecular formula: C13H9ClN2. Mole weight: 228.68. | |
| GDC-0623 | GDC-0623 is an orally active, selective MEK inhibitor with potential antineoplastic activity. MEK inhibitor GDC-0623 specifically inhibits mitogen-activated protein kinase kinase (MEK or MAP/ERK kinase), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers. Synonyms: GDC0623; GDC-0632; GDC 0632; G868; G 868; G-868. CAS No. 1168091-68-6. Molecular formula: C16H14FIN4O3. Mole weight: 456.216. | |
| GDC-0879 | GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(V600E) tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS-expressing tumors. Despite the involvement of activated RAF signaling in RAS-induced tumorigenesis, decreased time to progression was observed for some KRAS-mutant tumors following GDC-0879 administration. Moreover, striking differences were noted for RAF and MEK inhibition across a panel of 130 tumor cell lines. Whereas GDC-0879-mediated efficacy was associated strictly with BRAF(V600E) status, MEK inhibition also attenuated proliferation and tumor growth of cell lines expressing wild-type BRAF (81% KRAS mutant, 38% KRAS wild type). The responsiveness of BRAF(V600E) melanoma cells to GDC-0879 could be dramatically altered by pharmacologic and genetic modulation of phosphatidylinositol 3-kinase pathway activity. These data suggest that GDC-0879-induced signaling changes are dependent on the point of oncogenic activation within the RAS network. Taken together, these studies increase our understanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition and have implications for therapeutic intervention in the clinic. Synonyms: GDC0879; GDC-0879; GDC 0879. CAS No. 905281-76-7. Molecular formula: C19H18N4O2. Mole weight: 334.37182. | |
| GSK-3beta Inhibitor XXIV (2-Methyl-5- (3-[4- (methylsulfinyl) phenyl) -1-benzofuran-5-yl) -1, 3, 4-oxadiazole, Racemic) | An orally bioavailable and blood-brain-barrier permeable oxadiazolo-benzofuranyl phenyl sulfoxide compound that acts as a potent, reversible and ATP-competitive inhibitor of GSK-3b (IC50=35nM, 34 and 140nM for racemic, (S)-9b eutomer and (R)-9b distomer). The (S)-9b eutomer displays excellent selectivity (IC50 > 10uM) over Cdk1/2/5, Chk1, p38a, JNK1, MEKK1, IKKb, PKCth, CK1d, EGFR, ErbB2, Src, Lck, IR, Tie2, c-Kit, c-Met, VEGFR2, FGFR3 and PDGFRa/b, and lowers tau phosphorylation at GSK-3b-Thr205 in a CWS (cold water stress) mouse model (3mg/kg, p.o.). Group: Biochemicals. Grades: Highly Purified. CAS No. 1005201-24-0. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| GW284543 | GW284543 (UNC10225170) is a selective MEK5 inhibitor. It can reduce pERK5 and reduce endogenous MYC protein. Synonyms: CHEMBL531447; BCP31359; MFCD32067894; HY-114189. Grades: 98%. CAS No. 790186-68-4. Molecular formula: C23H20N2O3. Mole weight: 372.4. | |
| GW5074 | GW5074 is a c-Raf inhibitor. GW5074 has no direct effect on the activities of several apoptosis-associated kinases when assayed in vitro. In contrast to its effect in vitro, treatment of neurons with GW5074 causes c-Raf activation (when measured in vitro in the absence of the drug) and stimulates the Raf-MEK-ERK pathway. GW5074 prevents neurodegeneration and improves behavioral outcome in an animal model of Huntington's disease. GW5074 could have therapeutic value against neurodegenerative pathologies in humans. Synonyms: GW5074; GW 5074; GW-5074. CAS No. 220904-83-6. Molecular formula: C15H8Br2INO2. Mole weight: 520.94. | |
| Hymenialdisine | A potent inhibitor of a variety of kinases including MEK-1, GSK-3B, and CKI. It also exhibits inhibition of the G2 cell cycle checkpoint at the micromolar concentrations. Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| Hymenialdisine Analogue #1 (5-(2-Amino-5-oxo-1,5-dihydroimidazol-4-ylidene)-3,4,5,10-tetrahydro-2H-azepino[3,4-b]indol-1-one) | The indole derivative of Hymenialdisine, a potent inhibitor of a variety of kinases including MEK-1, GSK-3B, and CKI. It also exhibits inhibition of t. Group: Biochemicals. Alternative Names: 5-(2-Amino-5-oxo-1,5-dihydroimidazol-4-ylidene)-3,4,5,10-tetrahydro-2H-azepino[3,4-b]indol-1-one. Grades: Highly Purified. Pack Sizes: 1mg. US Biological Life Sciences. | Worldwide |
| Hypothemycin | Antifungal. Cytotoxic against some tumor cell lines, partly attributed to inhibition of Ras-inducible genes. Inhibits proliferation of mouse and human T cells. Modulates production of cytokines during T cell activation. Facilitates the ubiquitinylation process of cyclin D1. Potent and selective threonine/tyrosine-specific kinase, MEK and other protein kinases inhibitor in both in vitro and in vivo studies. Group: Biochemicals. Alternative Names: 3H-Oxireno [k] [2] benzoxacyclotetradecin-5, 11 (2H, 4H) -dione, 1a, 8, 9, 15b-tetrahydro-3, 4, 12-trihydroxy-14-methoxy-9-methyl-, (1aR, 3S, 4S, 6Z, 9S, 15bR) -, NSC354462. Grades: Highly Purified. CAS No. 76958-67-3. Pack Sizes: 250ug, 1mg. Molecular Formula: C??H??O?. US Biological Life Sciences. | Worldwide |
| Hypothemycin | Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K i s of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1 , MEK1/MEK2 , FLT-3 , PDGFRβ/PDGFRα , and ERK1/ERK2 , respectively [1] [2]. Uses: Scientific research. Group: Natural products. CAS No. 76958-67-3. Pack Sizes: 500 μg; 1 mg. Product ID: HY-107417. | |
| InSolution PD 98059 - CAS 167869-21-8 | PD 98059, CAS 167869-21-8, is a 5 mg/ml solution in DMSO. A a cell-permeable, selective & reversible inhibitor of MAP Kinase Kinase (MEK). Group: Fluorescence/luminescence spectroscopy. | |
| InSolution U0126 - CAS 109511-58-2 | A potent and specific inhibitor of MEK1 and MEK2. Group: Fluorescence/luminescence spectroscopy. | |
| Kinase Inhibitor Library | A unique collection of 2230 kinase inhibitors for high throughput screening and high content screening for drug discovery in kinase related diseases; - Bioactivity and safety confirmed by pre-clinical research and clinical trials, and some of them are approved by FDA; - Targets include MAPK, PI3K, JAK, STAT, CDK, MEK, Insulin/IGF receptors, CaM Kinease II, PKA, JNK, PKC, RAF, EGFR, SAPK, GSK, MLCK, Src-family, IKK, PDGFR, VEGFR, etc; - Detailed compound information with structure, target, activity, IC50 value, and biological activity description; - Structurally diverse, medicinally active, and cell permeable; - NMR and HPLC validated to ensure high purity and quality. Uses: Scientific use. Product Category: L1600. Categories: Kinase Inhibitor Libraries. |  |
| Lidocaine hydrochloride | Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence [1]. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Lignocaine hydrochloride. CAS No. 73-78-9. Pack Sizes: 10 mM * 1 mL; 500 mg; 5 g; 10 g. Product ID: HY-B0185A. | |
| Lysophosphatidylethanolamines, egg | Lysophosphatidylethanolamine (LPE) is a naturally-occurring lysophospholipid that can be generated via deacylation of phosphatidylethanolamine by phospholipase A2 (PLA2). It increases the phosphorylation of ERK1/2 in PC12 cells, an effect that can be blocked by the MEK inhibitors U-0126 (HY-12031A) and PD 98059 (HY-12028) and the EGFR inhibitor AG-1478 (HY-13524).1 LPE also increases neurite outgrowth and expression of neurofilament M in PC12 cells. LPE inhibits the activity of phospholipase D (PLD) partially purified from cabbage.3 This product contains lysophosphatidylethanolamine molecular species with variable fatty acyl chain lengths at the sn-1 position and a hydroxy group at the sn-2 position. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Lyso-PE (egg); LPE (egg); L-α-lysophosphatidylethanolamine. CAS No. 97281-40-8. Pack Sizes: 1 mg; 5 mg. Product ID: HY-156041. | |
Our database is helping our users find suppliers everyday.
